WHO Prequalification of APIs - Shanghai 2014 1 |1 | 1 1 3.2.S.3.2 Impurities, Malaysia, 29 September 2011 Active Pharmaceutical Ingredient (API) Prequalification.

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

Prequalification of HIV/AIDS Drugs - UN joint activity lPartners* –UNAIDS –UNICEF –UNFPA –WHO –With the support of World Bank lWHO –Manages, provides technical.
Introduction to WHO Prequalification of Medicines Programme Essential requirements Dr Milan Smid and many team colleagues WHO Prequalification of Medicines.
GMP Document and Record Retention
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
1 XXXXXXXXXXXXXXXXXXX, Malaysia, XXXXXX September, S.3.2 Impurities, Malaysia, 29 September 2011 Options for submitting API data to support.
UNICEF Medicines Supply Strengthening WHO Technical Briefing Seminar on Essential Medicines and Health Products Tuesday 29 October 2013 Technical Specialist.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
World Health Organization
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
WHO Prequalification of Medicines Programme General overview and update Dr Milan Smid WHO Prequalification of Medicines Programme Amman, June 2013.
1 WHO Procurement, Quality and Sourcing Project: Access to Tuberculosis Drugs of Acceptable Quality Experience from the Evaluation of Drug Dossiers with.
Structure of Dossier of Medicinal Product- Q part
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
Prequalification of Quality Control Laboratories WHO Quality Monitoring Projects Jitka Sabartova Prequalification Programme: Priority Essential Medicines.
Manufacturers' perceptions of WHO medicines prequalification Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances Amman, Jordan, 13.
WHO Prequalification – Medicines Finished Pharmaceutical Products Hua YIN
Business environment for WHO prequalified medicines Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances Amman, Jordan, 13 June 2013.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
WHO Prequalification of Diagnostics WHO Technical Briefing Seminar on Essential Medicines and Health Products WHO HQ, Geneva, 28 October - 1 November 2013.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Prequalification programme: Priority essential.
Systems Strengthening & Market Development Approaches Working Groups Addis Ababa 21 June 2011 Peter Hall, Chief Executive Officer, Concept Foundation.
Theo Dekker -- Jiaxing, China --September |2 | WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics.
UN Prequalification Programme
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
The PAHO Prequalification System External Quality Control Program of Official Drug Quality Control Laboratories (EQCP) José M. Parisi PAHO/WHO Costa Rica.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Approval Mechanism for Suppliers of Malaria Drugs and Nets Presentation by Dr Maryse Dugué RBM Partnership Secretariat, Malaria Medicines & Supplies Services.
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
Theo Dekker -- CPH -- Nov |2 | Meeting of WHO PQP with European manufacturers and EU holders of marketing authorisations WHO Prequalification of.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
UN / WHO Prequalification Programme for Priority Medicines
1 Regulatory capacity building and principles of Collaboration Procedure between the WHO Prequalification Programme and NMRAs Milan Smid WHO Prequalification.
1 WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 1 November 2011 Technical Specialist Henrik K.Nielsen, Medicines and Nutrition.
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
PQP-overview & update January Prequalification of Medicines Overview & update Wondiyfraw Z. Worku WHO Prequalification of Medicines Programme Assessment.
Prequalification of Medicines Overview & update
WHO Prequalification of Medicines Programme Raul Kiivet, MD, PhD Manager, Prequalification of Medicines Programme Quality Assurance and Safety: Medicines.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 The new PQP quality guideline.
UN Prequalification of Diagnostics, Medicines and Vaccines 5th Consultative Stakeholders Meeting, 11 February 2010 Prequalification of Medicines Dr Lembit.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
WHO Prequalification Programme Milan Smid, M.D., Ph.D. Prequalification Programme: Priority Essential Medicines.
UNICEF Medicines Supply Strengthening WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 30 October 2012 Technical Specialist.
Pogány - Hanoi 1/40 Training Workshop on Pharmaceutical Quality and Bioequivalence, January 2006 János Pogány, pharmacist, Ph.D. consultant.
Second African Medicines Regulators Conference^, 24 ‐ 26 November 2009, Maputo, Mozambique, Prequalification of Medicines Dr Lembit Rägo, Coordinator Quality.
TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
The WHO Prequalification of Medicines Program - Introduction Tony Gould Manager, Prequalification of Medicines Program WHO.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Leveraging the prequalification process for national regulatory decision making Fimbo, A. M Tanzania Food and Drugs Authority.
1 |1 | WHO Prequalification – Medicines Assessments Andrew Chemwolo, Technical Officer Prequalification Team – Medicines Assessment.
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
GDF Quality Assurance Processes
GMP Inspection Process
Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.
Quality Problems with Antimalarials
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
Assessment of Medicines
Update on WHO Prequalification of QCLs and Quality Monitoring Projects
The WHO Prequalification of Medicines Programme Dossier Assessment
Jitka Sabartova WHO Prequalification of Medicines Programme
Presentation transcript:

WHO Prequalification of APIs - Shanghai |1 | S.3.2 Impurities, Malaysia, 29 September 2011 Active Pharmaceutical Ingredient (API) Prequalification Dr Antony Fake WHO Prequalification Team - Medicines

WHO Prequalification of APIs - Shanghai |2 | API – Active Pharmaceutical Ingredient (drug substance) FPP – Finished Pharmaceutical Product (drug product) APIMF – Active Pharmaceutical Ingredient Master File (DMF) API-PQ –Active Pharmaceutical Ingredient Prequalification SRA – Stringent Regulatory Authority GMP – Good Manufacturing Practice PQP – Prequalification Team - Medicines Abbreviations

WHO Prequalification of APIs - Shanghai |3 | Prequalification Programme The Prequalification Team – Medicines (PQP) is responsible for ensuring that Medicines available to procurers (and national authorities) are of good quality. In order to have good quality medicines you must have: Good quality Active Pharmaceutical Ingredients.

WHO Prequalification of APIs - Shanghai |4 | The programme has two primary objectives: To ensure there is available essential APIs and FPPs that are of good quality. To support manufacturers of essential APIs and FPPs to meet international regulatory standards. Prequalification Programme

WHO Prequalification of APIs - Shanghai |5 | API Prequalification

WHO Prequalification of APIs - Shanghai |6 | What is API Prequalification? It is a scheme for manufacturers of APIs that are used in medicinal products for HIV, TB, Reproductive Health, Malaria, Neglected Tropical diseases and Zinc. It seeks to verify and identify APIs that are of good quality and manufactured in compliance with GMP. It commenced as a pilot project in October 2010.

WHO Prequalification of APIs - Shanghai |7 | Why is Prequalification of APIs needed? There is a relative scarcity of API. There are significant geographical distances between API and FPP manufacturers, i.e. between China and India. The quality and GMP status of the API manufacturer may not be clear. Medicine manufacturers involved in the PQ programme (and in general) have difficulties in finding sources of quality APIs for Malaria, HIV, Reproductive Health and TB, because: This creates basic problems for FPP manufacturers to find and establish contact with potential API manufacturers.

WHO Prequalification of APIs - Shanghai |8 | 6th Invitation for EOI Not all APIs are invited to apply for prequalification. APIs are publicly invited through a published invitation for expression of interest (EOI). A 6 th invitation for Expressions of Interest (EOI) has now been announced. It essentially covers those APIs listed in the associated FPP EOIs for HIV, anti-TB, Malaria, reproductive health neglected tropical diseases and Zinc. See website for the invitation:

WHO Prequalification of APIs - Shanghai |9 | 6th Invitation for EOI Invited Active Pharmaceutical IngredientTherapeutic area Abacavir, Atazanavir, Darunavir, Dolutegravir, Efavirenz, Emtricitabine, Etravirine, Lamivudine, Lopinavir, Nelfinavir, Nevirapine, Raltegravir, Ritonavir, Stavudine, Tenofovir, Zidovudine HIV Amodiaquine, Artemether, Artesunate, Dihydroartemisinin, Lumefantrine, Mefloquine, Piperaquine, Pyrimethamine, Pyronaridine, Sulfadoxine Anti-malarial Amikacin, Capreomycin, Clofazimine, Cycloserine, Ethambutol, Ethionamide, Isoniazid, Kanamycin, Levofloxacin, Linezolid, Moxifloxacin, PAS, PAS Sodium, Prothionamide, Pyrazinamide, Rifampicin, Streptomycin, Terizidone Anti-tuberculosis Desogestrel, Estradiol cypionate, Estradiol valerate, Ethinylestradiol, Etonogestrel, Levonorgestrel, Medroxyprogesterone acetate, Mifepristone, Misoprostol, Norethisterone enanthate, Norgestrel, Oxytocin Reproductive health Albendazole, Diethylcarbamazine citrate, Mebendazole, Praziquante NTD Zinc Sulphate Zinc Oseltamivir, Zanamivir Influenza

WHO Prequalification of APIs - Shanghai | Benefits to API manufacturers API’s can be prequalified independent of an FPP application. Public recognition as a source of quality API, manufactured in compliance with GMP. Serves as a point of difference between good quality and poor quality APIs. Opportunities to verify compliance with GMP. Opportunities to compile, revise and refine their regulatory documentation, leading to quicker acceptance by other national regulatory agencies. API PQ is increasingly recognised by National authorities.

WHO Prequalification of APIs - Shanghai | Benefits to FPP manufacturers Ease of identifying potential sources of quality API. Identifying API manufacturers with robust quality systems in place. Identifying API manufacturers that maintain good regulatory documentation, which may be used in regulatory submissions.

WHO Prequalification of APIs - Shanghai | Prequalification of Medicines website

WHO Prequalification of APIs - Shanghai | What is API Prequalification? API Manufacturer API Prequalification It is a scheme for API manufacturers only There is no involvement by FPP manufacturers

WHO Prequalification of APIs - Shanghai |ApplicationApplication Invitation Application Assessment (GMP) Assessment (Quality) Decision Publishing

WHO Prequalification of APIs - Shanghai |ApplicationApplication The PQ application form. An APIMF (if not previously provided). A Site Master File (if not previously provided). Any further evidence of GMP at the facility (optional). An application should consist of:

WHO Prequalification of APIs - Shanghai | Assessment – Quality (APIMF) Invitation Application Assessment (GMP) Assessment (Quality) Decision Publishing

WHO Prequalification of APIs - Shanghai | APIMF - Technical content Excellent technical guidance can be found in the module 3.2.S sections (pages 11 to 31) of the recently published guideline : Guideline on submission of documentation for a multisource (generic) finished pharmaceutical product (FPP): quality part. Guideline_Quality.pdf

WHO Prequalification of APIs - Shanghai | Assessment – GMP By providing evidence of current compliance: –GMP certificates, inspection reports, CAPAs, the most recently completed Product Quality Review (PQR) report. or By inspection by the WHO. There are two ways to demonstrate GMP compliance at the API manufacturing facility.

WHO Prequalification of APIs - Shanghai | Assessment – GMP Inspections performed previously by WHO, a member of PIC/S, or an SRA. Inspection must have occurred within 3 years of application. Inspections must be API specific. Assessment of GMP compliance at the site of API manufacture takes into account: The WHO will perform an inspection if, after assessment and requests for information, GMP compliance can not be established.

WHO Prequalification of APIs - Shanghai |PublishingPublishing Invitation Application Assessment (GMP) Assessment (Quality) Decision Publishing

WHO Prequalification of APIs - Shanghai |PublishingPublishing List of PQ APIs Website (Public) Confirmation Document (Private) + WHOPIRs Website (Public)

WHO Prequalification of APIs - Shanghai |PublishingPublishing The date of prequalification is the date when the API is published on the WHO List of Prequalified Active Pharmaceutical ingredients.

WHO Prequalification of APIs - Shanghai | WHO List of Prequalified APIs WHO application number. INN name. Date of prequalification. Name of the applicant Sites of API manufacture. The APIMF version number. The API specification version number. The primary and secondary packaging components. The assigned re-test period. The recommended storage conditions. Confirmation of API PQ document issue date Intended for: UN agencies, National medicine authorities, FPP manufacturers, public Publically available

WHO Prequalification of APIs - Shanghai | Confirmation of API PQ document The assigned WHO application number. The INN name of the active pharmaceutical ingredient. API manufacturer company name. The API specification version number. A copy of the API specifications. The assigned re-test period. The recommended storage conditions. A copy of the assay and related substances test methods. Provided to the API manufacturer for distribution at their discretion Intended for: UN agencies, National medicine authorities, FPP manufacturers

WHO Prequalification of APIs - Shanghai | Future of API Prequalification There is very positive feedback from FPP manufacturers whenever PQ of APIs is discussed. Applications and the number of prequalified APIs continues to increase. May 2014Dec 2013Dec 2012Dec Total number of applications Number of PQ APIs

WHO Prequalification of APIs - Shanghai | New procedures and guidance Elimination of paper based submission for APIs Introduction of electronic document requirements Introduction of a new Amendment guidance

WHO Prequalification of APIs - Shanghai | Use among NMRAs Efforts are being undertaken to increase the recognition of PQ APIs by NMRAs to further increase the value of participation and to reduce regulatory burden on NMRAs. This includes the use of Prequalified APIs in non-PQP FPPs. CPQs are now recognised by regulators of the East African Community as a means of submitting API information. CPQs are actively considered by many Southern African Regulators as a means of verifying API information. South Africa is currently considering recognition of CPQs.

WHO Prequalification of APIs - Shanghai | Further information The PQ website is a good source of information, please read. AND, ALSO Please me (or visit) if you have any questions. One could save you a lot of time.

WHO Prequalification of APIs - Shanghai | 谢谢你